Jason_Dengyuemed

Jason_Dengyuemed ha aggiunto una foto Health
2025-11-18 08:18:47 - Translate -

El Boom de los Fármacos Innovadores Chinos en el Mercado Global: DengYue Medicine se Une a los Líderes de la Exportación
En un año marcado por avances sin precedentes en la biotecnología, China se consolida como una potencia en la exportación de fármacos innovadores. Según informes recientes, las transacciones de salida de medicamentos innovadores chinos alcanzaron casi los 66 mil millones de dólares en la primera mitad de 2025, superando los totales anuales de...

0 Commenti 0 condivisioni 109 Views 0 Anteprima

Effettua l'accesso per mettere mi piace, condividere e commentare!
Jason_Dengyuemed ha aggiunto una foto Health
2025-10-21 08:02:03 - Translate -

China’s Pharmaceutical Exports Show New Momentum Amid Global Trade Shifts
The landscape of China’s pharmaceutical exports is entering a period of accelerated transformation, driven by changing global trade patterns, the rise of innovative drug development, and the diversification of global healthcare demand. In the past decade, China’s pharmaceutical exports were dominated by active pharmaceutical ingredients (APIs) and intermediate chemicals. Today,...

0 Commenti 0 condivisioni 449 Views 0 Anteprima

Effettua l'accesso per mettere mi piace, condividere e commentare!
Jason_Dengyuemed ha aggiunto una foto Health
2025-09-27 08:28:34 - Translate -

Flyrcado™ : A Breakthrough In Cardiac PET Imaging For Coronary Artery Disease
In a landmark advancement for nuclear cardiology, GE HealthCare has launched Flyrcado™ (flurpiridaz F 18), the first FDA-approved unit-dose positron emission tomography (PET) myocardial perfusion imaging (MPI) agent for detecting coronary artery disease (CAD). Approved in September 2024 and commercially available in select U.S. markets...

0 Commenti 0 condivisioni 568 Views 0 Anteprima

Effettua l'accesso per mettere mi piace, condividere e commentare!
Jason_Dengyuemed ha aggiunto una foto Health
2025-09-23 07:54:41 - Translate -

Ionis Launches Tryngolza™ (Olezarsen) for FCS With Positive Phase 3 Data and $595,000 Annual List Price
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the official U.S. launch of Tryngolza™ (olezarsen), a novel, once-monthly RNA-targeted therapy for familial chylomicronemia syndrome (FCS). The drug enters the market at an annual list price of $595,000, following its FDA approval in December 2024. First FDA-Approved Olezarsen Therapy for...

0 Commenti 0 condivisioni 678 Views 0 Anteprima

Effettua l'accesso per mettere mi piace, condividere e commentare!
Jason_Dengyuemed updated the profile picture
2025-09-18 09:26:17 - Translate -

0 Commenti 0 condivisioni 242 Views 0 Anteprima

Effettua l'accesso per mettere mi piace, condividere e commentare!

Altre storie